HutchMed Reports 2022 Financial Results with Revenue Growth
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...
Boao Lecheng pilot zone
Sanofi’s Sarclisa Approved for Import in Shenzhen via Greater Bay Area Scheme
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced import approval in Shenzhen via the Greater...
Enhertu Approved in China for HER2-Positive Breast Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and...
AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval
UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at...
Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...
Meihua International Partners with Hainan for Medical Tech Park and R&D Center
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), a specialist in Chinese medical consumables, has...
WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services
China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...
Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...
SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Junshi Biosciences’ JS401 Accepted for Review by China’s NMPA for Hyperlipidemia
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the National Medical Products Administration...
CDE Grants Priority Review to Takeda’s Vonicog Alfa, Zhongmei’s Rilonacept, and Zai Lab’s SUL-DUR
The Center for Drug Evaluation (CDE) has indicated that Takeda’s Vonicog alfa, Zhongmei Huadong Pharma’s...
Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China
China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...
Pfizer’s Nurtec ODT Launches in China via Hainan’s Bo’Ao Lecheng Zone
US-based Pfizer’s (NYSE: PFE) Nurtec ODT (rimegepant), the world’s first calcitonin gene-related peptide (CGRP) receptor...
InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...
Huadong Medicine’s Lanluma V and X Approved for Use in Hainan
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval from the Hainan Medical...
Antengene Files for Xpovio Approval in Macau, Malaysia, and Thailand
Antengene Corp., Ltd (HKG: 6996) has announced market filings for its Xpovio (selinexor) in Macau,...
InnoCare Receives CDE Approval for Phase II Trial of Orelabrutinib Combination
China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving approval from China’s Center...
Novartis China Establishes Health Development Fund in Boao Lecheng
Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...
Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange
China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...